SmithKline Beckman Corp said it and&lt;Boehringer Mannheim GmbH> signed a final agreement to developand market new cardiovascular medicines discovered byBoehringer.    Under the agreement, SmithKline said, it will haveresponsibility for developing the products in the U.S. Bothpartners will market the products in the U.S. and abroad.    Initially, SmithKline said, the companies will concentrateon the clinical development and marketing of carvedilol whichis a compound to treat mild to moderate hypertension andangina.       An application for marketing approval of carvedilol wassubmitted in West Germany last December, SmithKline said.Applications expected in other European markets this year andsubmission to the U.S. Food and Drug Administration isprojected for 1990.    It said work also underway on thromboxane receptorantagonists, compounds which could be useful in acceleratingdisolution of blood clots and preventing blod clots fromoccuring in a heart attack as well as in other arterialdiseases. The company said two of these compounds are inclinical evaluation in Europe and the U.S. Reuter&#3;